Professor of Medicine, University Maryland School of Medicine Director, Breast Evaluation and Treatment Program University of Maryland Greeneabum Cancer Center,
Oncology
Dr. Katherine H. Tkaczuk, MD
|
|
Give Review
Katherine Tkaczuk is an expert in the field of Oncology. She attended Wroclaw Medical University. She over the years received 5 awards: "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area" and "Top Doctors:Washington-Baltimore". Katherine Tkaczuk is also published. She has 37 publications published. The lastest publication: "Suramin, an active drug for prostate cancer: interim observations in a phase I trial.' She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.
- Development of a qPCR method to rapidly assess the function of NKT cells.
- mTOR inhibitors: changing landscape of endocrine-resistant breast Cancer.
- Increasing national mastectomy rates for the treatment of early stage breast Cancer.
- Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast Cancer.
- Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primar...
- Can obesity explain the racial difference in stage of breast Cancer at diagnosis between black and white women?
- Body mass and stage of breast Cancer at diagnosis.
- A pilot study of FDG PET/CT detects a link between brown adipose tissue and breast Cancer.
- Accelerated partial breast irradiation via brachytherapy: A patterns-of-care Analysis with ASTRO consensus statement groupings.
- Readers respond to "balancing evidence-based medicine and cultural competence in the quest to end healthcare disparities".
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive brea...
- Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid Tumors.
- Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast Cancer patients treated with doc...
- A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and Leukemia group B 9661.
- Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast Cancer.
- Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast Cancer refractory to paclitaxel.
- Exploring patient-physician communication in breast Cancer care for African American women following primary treatment.
- Aging may be associated with concentrations of tamoxifen and its metabolites in breast Cancer patients.
- Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast Cancer.
- Profiles of tamoxifen-related side effects by race and smoking status in women with breast Cancer.
- Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosp...
- Surveillance for uterine abnormalities in tamoxifen-treated Breast carcinoma survivors: a community based study.
- Social support as a buffer to the psychological impact of stressful life events in women with breast Cancer.
- Phase I study of docetaxel and topotecan in patients with solid Tumors.
- A phase I study of paclitaxel, UFT, and leucovorin.
- Suramin, an active drug for prostate Cancer: interim observations in a phase I trial.
- Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate...
- Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate Cancer.
- Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid Tumors.
- Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in ...
- Computer assisted quantitative immunofluorescence of tumor tissue marker expression and clinical outcome to chemotherapy in advanced breast Cancer patients.
- Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast Cancer.
- Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing Breast tumor cells.
- Evidence-based care for breast Cancer survivors: communicating the Institute of Medicine Guidelines in medical practice.
- The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method.
Schools
We Wroclawiu Im Piastow Slaskich Academy of Medicine
St Agnes Hospital
University MD Canc Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
Education
-
University of Maryland -
Wroclaw Medical University
Hospital
-
University of Maryland Baltimore Washington Medical Center -
University of Maryland Medical Center
Drug Facts
| NPI NUMBER | 1225079601 | |
| NPPES Provider LastName | TKACZUK | |
| NPPES Provider FirstName | KATHERINE | |
| NPPES Provider ZIPCode | 212011544 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 483.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 35.0 | |
| Percent Opioid Claims | 7.25 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225079601 |
| Last Name Of The Provider | TKACZUK |
| First Name Of The Provider | KATHERINE |
| View All |
Similar Doctors
|
|
Dr. Yvette L. Kasamon, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Madhu Chaudhry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ting Bao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher A. Klebanoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hyam I. Levitsky, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ephraim J. Fuchs, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Carol A. Huff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heather A. Parsons, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. B D. Smith Jr., MD |